The LIVE-AIR phase 3 clinical trials associated with early treatment of hyperinflammatory response with the humanized monoclonal antibody– lenzilumab – in COVID-19 patients with decreased oxygen saturation, could prove that the treatment significantly enhanced the possibility of survival without invasive mechanical ventilation. The trial results revealed that the primary end point, the efficacy parameter of lenzilumab for the treatment of COVID in patients with decreased oxygen saturation, has been established.  The study results, posted on medRxiv preprint server, said that lenzilumab significantly enhanced the possibility of survival as compared with the controlled group who were treated with a placebo. The researchers shared that 520 participants were present in the trial and that marked improvements were noted in patients as compared to the placebo, which was also well-tolerated without causing any adverse effects.